Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.100
+0.190 (4.86%)
At close: Jul 16, 2026, 4:00 PM EDT
4.020
-0.080 (-1.95%)
After-hours: Jul 16, 2026, 4:10 PM EDT
Molecular Partners AG Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
134
Market Cap
150.35M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | 2.49M | 9.37% |
| Dec 31, 2014 | 26.63M | -5.79M | -17.87% |
| Dec 31, 2013 | 32.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 20.99M |
| Alector | 18.42M |
| Pyxis Oncology | 13.86M |
| Armata Pharmaceuticals | 5.20M |
| Kazia Therapeutics | 1.27M |
| YD Bio | 510.36K |
| Connect Biopharma Holdings | 233.00K |
MOLN News
- 21 hours ago - Molecular Partners doses first patients in MP0317 combination study - TheFly
- 2 days ago - Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference - GlobeNewsWire
- 10 days ago - Molecular Partners To Advance MP0726 For First Human Imaging In H2,2026; Provides MP0712 Update - Nasdaq
- 11 days ago - Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics - GlobeNewsWire
- 14 days ago - Molecular Partners, Orano Med doses first patient in MP0712 study - TheFly
- 15 days ago - Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 - GlobeNewsWire
- 6 weeks ago - Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study - TheFly
- 6 weeks ago - Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 - GlobeNewsWire